<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hospital-acquired and ventilator-associated pneumonia in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Klompas, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hospital-acquired (or nosocomial) pneumonia (HAP) is an important cause of morbidity and mortality despite improved prevention, antimicrobial therapy, and supportive care [<a href="#rid1">1</a>].</p><p>The treatment of non-ventilator-associated HAP (nvHAP) and ventilator-associated pneumonia (VAP) will be reviewed here. The diagnosis, epidemiology, pathogenesis, microbiology, risk factors, and prevention of nvHAP and VAP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p>Treatment of respiratory infections in pregnant individuals is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4793.html" rel="external">"Approach to the pregnant patient with a respiratory infection", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Pneumonia types</span><span class="headingEndMark"> — </span>Pneumonia is frequently categorized based on site of acquisition  (<a class="graphic graphic_table graphicRef130821" href="/z/d/graphic/130821.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital-acquired (or nosocomial) pneumonia (HAP)</strong> is pneumonia that occurs 48 hours or more after admission to the hospital and did not appear to be incubating at the time of admission. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventilator-associated pneumonia (VAP)</strong> is a type of HAP that develops in intubated patients on mechanical ventilation for more than 48 hours. VAP also includes HAP that occurs within 48 hours of extubation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-ventilator-associated HAP (nvHAP)</strong> refers to HAP that develops in hospitalized patients who are not on mechanical ventilation nor underwent extubation within 48 hours before pneumonia developed. nvHAP can be divided into patients that ultimately require mechanical ventilation (vHAP) due to the pneumonia versus those that do not. vHAP is associated with particularly poor clinical outcomes. </p><p></p><p>The category of health care-associated pneumonia (HCAP) is no longer recognized as a separate category of pneumonia and was purposefully not included in the 2016 and 2019 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) HAP [<a href="#rid1">1</a>] and CAP [<a href="#rid2">2</a>] guidelines or the combined 2017 European and Latin American HAP guidelines [<a href="#rid3">3</a>]. Historically, HCAP referred to pneumonia acquired in health care facilities such as nursing homes, hemodialysis centers, outpatient clinics, or within three months following a hospitalization [<a href="#rid4">4</a>]. This category was used to identify patients at risk for infection with multidrug-resistant (MDR) pathogens. However, this categorization may have been overly sensitive and may have led to increased, inappropriate broad antibiotic use. Although patients with recent contact with health care facilities are at increased risk for infection with MDR pathogens, this risk is small for most patients and the overall incidence of MDR pathogens in this population is low [<a href="#rid5">5-11</a>]. </p><p>We manage patients who would have been previously classified as having HCAP in a similar way to those with community-acquired pneumonia (CAP), deciding whether to include therapy targeting MDR pathogens on a case-by-case basis depending upon each patient's specific risk factors and severity of illness [<a href="#rid2">2</a>]. Specific risk factors for resistance that should be assessed include known colonization with MDR pathogens, recent receipt of antimicrobials, comorbidities, functional status, and severity of illness [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Antimicrobial resistance</span><span class="headingEndMark"> — </span>The United States Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) have developed standard terminology for antimicrobial-resistant gram-negative bacilli, which are potential causes of nvHAP and VAP [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>MDR refers to acquired nonsusceptibility to at least one agent in three different antimicrobial classes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensively drug resistant (XDR) refers to nonsusceptibility to at least one agent in all but two antimicrobial classes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pandrug resistant (PDR) refers to nonsusceptibility to all antimicrobial agents that can be used for treatment.</p><p></p><p>Awareness of local resistance patterns is critical for decisions regarding empiric therapy for HAP and VAP [<a href="#rid15">15</a>]. All hospitals should regularly create and disseminate a local antibiogram, ideally one that is specific to the different units in the hospital (although small numbers of cases per unit may preclude this) [<a href="#rid1">1</a>].</p><p>Risk factors for multidrug resistance are discussed separately. (See <a class="local">'Identifying risk factors for MDR pathogens'</a> below and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'MDR risk factors'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EMPIRIC THERAPY</span></p><p class="headingAnchor" id="H931548872"><span class="h2">Timing of antibiotics</span><span class="headingEndMark"> — </span>Once non-ventilator-associated HAP (nvHAP) or ventilator-associated pneumonia (VAP) is suspected clinically, microbiological specimens should be obtained as soon as possible in all patients. In patients with signs of septic shock or rapidly progressive organ dysfunction, antimicrobial therapy should be started as soon as possible [<a href="#rid1">1</a>]. If the diagnosis of nvHAP and VAP is uncertain and the patient is not in sepsis or septic shock, then it appears to be safe and potentially beneficial to gather more data and await culture results before treating [<a href="#rid16">16-19</a>]. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Empiric antibiotic therapy (first hour)'</a>.)</p><p>We pair early and aggressive treatment for patients with signs of sepsis or septic shock with early and aggressive de-escalation once the causative pathogen and susceptibilities are known or an alternative diagnosis is established (see <a class="local">'Tailoring therapy'</a> below). Long delays in treatment and/or failing to give a regimen with activity against the causative pathogens are both associated with higher mortality rates in patients with septic shock due to nvHAP or VAP [<a href="#rid20">20-23</a>]. However, broader regimens and longer treatment courses increase the risks of adverse drug effects, <em>Clostridioides</em> <em>difficile</em> infections, and antimicrobial resistance [<a href="#rid24">24,25</a>]. The difficulty in diagnosis may lead to overtreatment and its attendant risks of superinfection and antibiotic toxicity, but establishing the diagnosis of nvHAP and VAP can be difficult, especially for hospitalized patients in whom clinical, radiologic, and microbiologic findings can be due to numerous etiologies besides pneumonia. (See  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a>.)</p><p class="headingAnchor" id="H908114086"><span class="h2">Identifying risk factors for MDR pathogens</span></p><p class="headingAnchor" id="H2783985919"><span class="h3">Ventilator-associated pneumonia</span><span class="headingEndMark"> — </span>Risk factors for multidrug-resistant (MDR) pathogens in patients with VAP include the following  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for MDR pathogens (including </strong><strong><em>Pseudomonas aeruginosa</em></strong><strong>, other gram-negative bacilli, and methicillin-resistant </strong><strong><em>S. aureus</em></strong><strong> [MRSA]):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous (IV) antibiotic use within the previous 90 days</p><p class="bulletIndent2"><span class="glyph">•</span>Septic shock at the time of VAP</p><p class="bulletIndent2"><span class="glyph">•</span>Acute respiratory distress syndrome (ARDS) preceding VAP</p><p class="bulletIndent2"><span class="glyph">•</span>≥5 days of hospitalization prior to the occurrence of VAP</p><p class="bulletIndent2"><span class="glyph">•</span>Acute renal replacement therapy prior to VAP onset</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors specifically for MDR </strong><strong><em>Pseudomonas</em></strong><strong> </strong><strong><em>aeruginosa</em></strong><strong> and other gram-negative bacilli</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in an intensive care unit (ICU) in which &gt;10 percent of gram-negative bacilli associated with VAP are resistant to <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and/or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> </p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in an ICU in which local antimicrobial susceptibility rates among gram-negative bacilli are not known</p><p class="bulletIndent2"><span class="glyph">•</span>Colonization with <strong>and/or</strong> prior isolation of MDR <em>Pseudomonas</em> or other gram-negative bacilli on culture from any body site (but especially from the respiratory tract)</p><p></p><p class="bulletIndent1">Early detection of resistance genes by a multiplex polymerase chain reaction (PCR) panel can also provide early information regarding the presence of MDR pathogens [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">While presence of structural lung disease (eg, bronchiectasis, cystic fibrosis) in and of itself does not select for MDR pathogens, it can be a proxy for MDR risk since these patients are prone to frequent exposure to antimicrobials because of their increased risk for recurrent pneumonias. Repeated exposure to antimicrobials in turn increases risk for MDR pathogens. Generally, we treat patients with presence of structural lung disease with broad-spectrum antibiotics only if they have additional risk factors for VAP (such as known colonization with MDR pathogens or recent exposure to antibiotics), similar to the general population. It is important to be cautious about avoiding overuse of broad-spectrum antibiotics in this patient population to minimize further selection for resistance. Sometimes this may mean withholding antibiotics in patients who are not very sick or very frail until there is more diagnostic clarity of whether a pneumonia is truly present or not. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors specifically for MRSA</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in a unit in which &gt;10 to 20 percent of <em>S. aureus </em>isolates associated with VAP are methicillin resistant</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in a unit in which the prevalence of MRSA is not known</p><p class="bulletIndent2"><span class="glyph">•</span>Colonization with <strong>and/or</strong> prior isolation of MRSA on culture from any body site (but especially the respiratory tract)</p><p></p><p>Risk factors for MDR VAP have been addressed in several studies. In a meta-analysis conducted by the 2016 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines that included 15 studies, factors associated with an increased risk of MDR VAP were use of IV antibiotics in the past 90 days (odds ratio [OR] 12.3, 95% CI 6.48-23.35), ≥5 days of hospitalization prior to the occurrence of VAP, septic shock at the time of VAP (OR 2.01, 95% CI 1.12-3.61), ARDS before VAP (OR 3.1, 95% CI 1.88-5.1), and renal replacement therapy prior to VAP (OR 2.5, 95% CI 1.14-5.49) [<a href="#rid1">1</a>]. Coma present at the time of ICU admission was associated with lower risk of MDR VAP (OR 0.21, 95% CI 0.08-0.52). </p><p>Note that the prevalence of MRSA has been decreasing worldwide [<a href="#rid27">27-29</a>], which serves as an important reminder to consider the local prevalence when determining whether or not to include coverage for MRSA in an empiric regimen.</p><p class="headingAnchor" id="H910438516"><span class="h3">Non-ventilator-associated hospital-acquired pneumonia</span><span class="headingEndMark"> — </span>Risk factors for MDR pathogens and/or mortality in patients with nvHAP include the following  (<a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for increased mortality</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Need for ventilatory support for hospital-acquired (or nosocomial) pneumonia (HAP)</p><p class="bulletIndent2"><span class="glyph">•</span>Septic shock</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factor for MDR </strong><strong><em>Pseudomonas</em></strong><strong>, other gram-negative bacilli, and MRSA</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IV antibiotics within the past 90 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for MDR </strong><strong><em>Pseudomonas </em></strong><strong>and other gram-negative bacilli</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colonization with <strong>and/or</strong> prior isolation of MDR <em>Pseudomonas</em> or other gram-negative bacilli on culture at any body site (but especially the respiratory tract) </p><p></p><p>While presence of structural lung disease (eg, bronchiectasis, cystic fibrosis) in and of itself does not select for MDR pathogens, it can be a proxy for MDR risk since these patients are prone to frequent exposure to antimicrobials because of their increased risk for recurrent pneumonias. Repeated exposure to antimicrobials in turn increases risk for MDR pathogens. Generally, we treat patients with presence of structural lung disease with broad-spectrum antibiotics only if they have additional risk factors for VAP (such as known colonization with MDR pathogens or recent exposure to antibiotics), similar to the general population. It is important to be cautious about avoiding overuse of broad-spectrum antibiotics in this patient population to minimize further selection for resistance. Sometimes this may mean withholding antibiotics in patients who are not very sick or very frail until there is more diagnostic clarity of whether a pneumonia is truly present or not. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for MRSA</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in a unit in which &gt;20 percent of <em>S. aureus </em>isolates associated with HAP are methicillin resistant</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment in a unit in which the prevalence of MRSA is not known</p><p class="bulletIndent2"><span class="glyph">•</span>Colonization with <strong>and/or</strong> prior isolation of MRSA on culture at any body site (but especially the respiratory tract) </p><p></p><p class="headingAnchor" id="H2383820981"><span class="h2">Choosing an empiric regimen</span><span class="headingEndMark"> — </span>Empiric regimens for VAP  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a>) and nvHAP  (<a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>) are outlined in the algorithms. </p><p>Empiric regimens for VAP and nvHAP are determined by multiple factors [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Local known distribution of pathogens causing VAP and nvHAP and their antimicrobial susceptibility patterns  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>) [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient's individual risk factors for multidrug resistance  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>), including [<a href="#rid1">1,30</a>]: </p><p class="bulletIndent2"><span class="glyph">•</span>Recent antibiotic therapy (if patients have recently received antibiotics, empiric therapy should generally be with a drug from a different class since earlier treatment may have selected for pathogens resistant to the initial class).</p><p class="bulletIndent2"><span class="glyph">•</span>Prior microbiology data (colonization with <strong>or </strong>prior isolation of MDR pathogens on culture from any body site).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential adverse effects of antimicrobial agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential drug interactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient's severity of illness – the necessity of immediate, active antibiotics is greatest for patients with septic shock. The margin for error is greater for patients with less severe illness, allowing for the possibility of starting with a narrower empiric regimen and monitoring closely. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results of a good-quality Gram stain – a good-quality Gram stain can be useful for guiding the choice of initial therapy in patients without septic shock in whom antibiotics can be delayed until there is better diagnostic certainty of nvHAP or VAP. As an example, in a multicenter randomized trial of 206 patients with VAP, clinical cure (response) was noninferior in the group whose empiric antibiotic regimen was guided by Gram stain results compared with the group whose treatment was guided by guidelines (77 versus 72 percent; risk difference 0.05, 95% CI -0.07 to 0.17) [<a href="#rid31">31</a>]. Furthermore, the Gram stain group had reduced use of empiric anti-pseudomonal (70 versus 100 percent) and anti-MRSA agents (61 versus 100 percent) without significant difference in 28-day ICU-free days, ventilator-free days, or mortality between the two groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results of PCR multiplex – Identification of a probable pathogen on sputum PCR multiplex can be useful for guiding the choice of initial therapy. However, it is not yet widely available in all centers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug cost and availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinician's familiarity with different antibiotics.</p><p></p><p>In keeping with the 2016 HAP and VAP guidelines, we try to assure that ≥95 percent of patients with clear evidence of VAP and signs of severe illness receive empiric therapy with activity against the most likely pathogens, because patients with severe illness experience worse outcomes if initial antimicrobial therapy is ineffective against the causative pathogen [<a href="#rid1">1</a>]. In a meta-analysis of three small observational studies of patients with VAP, delays in appropriate therapy of &gt;24 to 48 hours were associated with significantly increased odds of mortality (OR 3.03, 95% CI 1.12-8.19) [<a href="#rid20">20</a>]. </p><p>Early and aggressive treatment should be paired with active efforts to narrow, tailor, or stop antibiotics as soon as it is safe to do so. Antimicrobial stewardship reduces rates of nosocomial infections (ie, <em>C. difficile</em>, MRSA, vancomycin-resistant enterococcal infections, and MDR gram-negative infections) and antimicrobial expenditures without increasing mortality or extending length of hospital stay [<a href="#rid32">32-36</a>]. (See  <a class="medical medical_review" href="/z/d/html/13943.html" rel="external">"Antimicrobial stewardship in hospital settings"</a>.) </p><p>All hospitals should regularly create and disseminate local antibiograms, ideally ones that are specific to their different units. Ideally, local resistance rates should be determined for each hospital unit and derived from pulmonary culture results from patients with VAP [<a href="#rid37">37</a>]. The resistance rate calculation should account for both the frequency of pathogens causing VAP and their resistance rates, resulting in a blended estimate of the probability that any given antibiotic will be active [<a href="#rid1">1,38</a>]. Because most hospitals do not have sufficient numbers of VAP isolates or data management support to generate such estimates, unit-wide or hospital-wide MRSA and <em>P. aeruginosa</em> resistance rates are acceptable, albeit conservative, proxies.</p><p>The recommendations below are generally in keeping with the 2016 ATS/IDSA guidelines on the management of HAP and VAP [<a href="#rid1">1</a>] (see <a class="local">'Society guideline links'</a> below). Modifications to these recommendations have been made based on the availability of newer agents that were not widely available at the time of the guideline's publication; further modifications may be needed based on the local prevalence of pathogens and local and hospital antimicrobial resistance patterns. The 2017 combined European and Latin American guidelines differ somewhat in their approach to initial antibiotic selection, opting to reserve empiric treatment for <em>Pseudomonas</em> species for those who are critically ill or have specific risk factors in an effort to reduce antimicrobial resistance [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H444746876"><span class="h3">Spectrum of activity of empiric therapy</span><span class="headingEndMark"> — </span>All empiric therapy regimens for VAP and nvHAP should include agents with activity against <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>, and other gram-negative bacilli. Regimens are stratified based on the patient's presence of MDR pathogen risk factors. Occasionally, consideration for other pathogens is warranted, as is described below: </p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Legionella</em></strong><strong> spp</strong> – Patients who have compromised immune systems, diabetes mellitus, renal disease, structural lung disease, or have been recently treated with glucocorticoids are at increased susceptibility for <em>Legionella</em> spp pneumonia. However, since nosocomial <em>Legionella</em> pneumonia is quite rare, we generally only add empiric anti-<em>Legionella</em> therapy (eg, with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> or a fluoroquinolone) for patients in whom the clinical syndrome is consistent with <em>Legionella</em> pneumonia (eg, severe illness, bilateral patchy infiltrates), when there is a known <em>Legionella</em> spp outbreak, or if the patient is not improving on initial empiric therapy (see <a class="local">'No clinical improvement after 48 to 72 hours'</a> below). Nosocomial cases of nvHAP and VAP due to <em>Legionella</em> spp attributable to contamination of the hospital water supply have been reported. (See  <a class="medical medical_review" href="/z/d/html/7025.html" rel="external">"Treatment and prevention of <i>Legionella</i> infection", section on 'Nosocomial pneumonia'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaerobes </strong>– Anaerobes are rarely implicated in VAP and anti-anaerobic therapy is generally not necessary [<a href="#rid39">39</a>]. We consider empiric treatment against anaerobes (beta-lactam-beta-lactamase inhibitor, a carbapenem, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>) in patients with frank and/or gross aspiration (inhalation of vomitus), poor dentition, recent abdominal surgery, presence of possible lung abscess, or if not improving on initial empiric therapy (see <a class="local">'No clinical improvement after 48 to 72 hours'</a> below). Anti-anaerobic empiric therapy may also be considered if a good-quality (eg, from BAL) Gram stain demonstrates polymicrobial organisms or polymicrobial oral flora as those findings increase the likelihood of anaerobic bacterial presence. (See  <a class="medical medical_review" href="/z/d/html/5520.html" rel="external">"Anaerobic bacterial infections"</a> and  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults", section on 'Choice of regimen'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Stenotrophomonas</em></strong><strong> spp </strong>– We do not generally administer empiric therapy for <em>Stenotrophomonas</em> species unless it has been detected on the patient's previous respiratory cultures, there is an outbreak of <em>Stenotrophomonas</em> spp present at the institution, or the patient is not improving on initial empiric therapy. (See <a class="local">'No clinical improvement after 48 to 72 hours'</a> below and  <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia", section on 'Pulmonary infection'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viruses and fungi </strong>–<strong> </strong>It is important to keep in mind that not all HAP/VAP is caused by bacteria. Viruses (eg, coronavirus disease-2019 [COVID-19], influenza) and fungi can cause similar clinical presentations, especially in patients with severe immunocompromise [<a href="#rid40">40</a>]. We routinely test for circulating respiratory viruses in patients with suspected HAP, particularly during respiratory viral surges and seasons. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment", section on 'Hospitalized patients'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">"Nonresolving pneumonia"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of prior culture data</strong> – Prior respiratory isolates should also guide antibiotic selection. A patient with a history of a pathogen in their sputum (eg, <em>Acinetobacter</em> spp) should receive empiric therapy with activity against the previous isolate if they have severe pneumonia. </p><p></p><p>Specific regimens are presented in the following section.</p><p class="headingAnchor" id="H1471949531"><span class="h3">Regimens</span><span class="headingEndMark"> — </span>The dosing provided below is intended for patient with normal renal function; dosing will need to be adjusted in those with renal dysfunction. When available, choice of antibiotics should be guided based on local antibiogram resistance rates. </p><p class="headingAnchor" id="H2290239769"><span class="h4">No risk factors present</span><span class="headingEndMark"> — </span>For patients with nvHAP/VAP who have <strong>no</strong> known risk factors for MDR pathogens  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>) and no increased mortality risk for those with nvHAP, we suggest a regimen that has activity against <em>Pseudomonas</em>, other gram-negative bacilli, and methicillin-susceptible <em>S. aureus </em>(MSSA). Preferred intravenous empiric antibiotic regimens include one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">Piperacillin-tazobactam</a> 4.5 g IV every 6 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> 2 g IV every 8 hours </p><p></p><p>We generally prefer <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> because they are more likely to have activity against gram-negative bacilli than the fluoroquinolones, although preference should be guided by local antibiograms, when available. However, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 750 mg IV daily may be preferred if there is a high suspicion for <em>Legionella</em> spp infection and local resistance rates of <em>S. aureus</em>, <em>P. aeruginosa</em>, and other gram-negative bacilli to fluoroquinolones are low (see <a class="local">'Spectrum of activity of empiric therapy'</a> above). The ATS/IDSA guidelines also include <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> as options, but we generally reserve these agents for patients with a high likelihood of infection with an extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacillus or for patients in units where local antibiograms favor these agents over other broad-spectrum beta-lactams. (See <a class="local">'Gram-negative pathogens'</a> below.)</p><p>We do not use <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> as a preferred agent because it has less activity against MSSA than the other beta-lactams suggested above for HAP and VAP. When ceftazidime is used for empiric therapy, an additional agent with activity against <em>S. aureus</em> (eg, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) should also be used.</p><p>In patients with renal insufficiency, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> has been associated with neurotoxicity including seizures. Patients at risk should be closely monitored or alternative beta-lactams should be used. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Neurologic reactions'</a>.)</p><p>In general, HAP patients who are not in the ICU tend to be less severely ill than VAP patients, and, therefore, the negative consequences of initial inappropriate antibiotic therapy may be less pronounced with non-ICU nvHAP than with VAP. In addition, MDR pathogens tend to be less common in patients who develop HAP outside of the ICU, particularly early in the hospitalization course (see  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Microbiology'</a>). For this reason, the 2016 HAP and VAP guidelines suggest that a smaller subset of patients with HAP as compared with VAP require empiric treatment for MRSA and MDR gram-negative organisms [<a href="#rid1">1</a>]. A single agent active against both MSSA and <em>P. aeruginosa</em> is often sufficient.</p><p class="headingAnchor" id="H863642451"><span class="h4">Risk factors for MDR gram-negative bacilli</span></p><p class="headingAnchor" id="H245545074"><span class="h5">No history of carbapenem-resistant pathogens</span><span class="headingEndMark"> — </span>For patients with VAP or nvHAP who have risk factors for MDR gram-negative bacilli and no history of carbapenem-resistant pathogens, we suggest <strong>one of the following </strong> (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">Meropenem</a> 1 g IV every eight hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">Imipenem</a> 500 mg IV every six hours </p><p></p><p>Patients at risk of seizures from <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> (eg, renal insufficiency, underlying central nervous system [CNS] disease) should be closely monitored or alternative beta-lactams should be used (see  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Neurologic reactions'</a>). Patients who cannot tolerate carbapenems as a class can be given an alternative agent as discussed in the section below. (See <a class="local">'History of carbapenem-resistant pathogens'</a> below and <a class="local">'Allergy to penicillins or cephalosporins'</a> below.)</p><p>Risk factors for MDR gram-negative bacilli increase the risk for the presence of extended-spectrum beta-lactamase (ESBL)-producing and ampC-producing pathogens. Patients infected with these MDR pathogens have demonstrated better clinical outcomes when treated with carbapenems rather than other broad-spectrum antibiotics, such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> [<a href="#rid41">41</a>]. As an example, in a randomized trial of 391 patients with ESBL-producing <em>E.coli</em> or <em>K. pneumoniae</em> bloodstream infections, 3-day mortality was significantly lower in those who received <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> compared with piperacillin-tazobactam (4 versus 12 percent) [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H3430988736"><span class="h5">History of carbapenem-resistant pathogens</span><span class="headingEndMark"> — </span>For patients with prior respiratory culture data demonstrating gram-negative bacilli that are resistant to carbapenems, we suggest empiric monotherapy with one of the following agents: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a> 2.5 g IV every eight hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a> 3 g IV every eight hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">Imipenem-cilastatin-relebactam</a> 1.5 g IV every six hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">Meropenem-vaborbactam</a> 4 g every eight hours </p><p></p><p>Selection among these antibiotics is guided by availability and patient's prior culture and susceptibility data, when available. <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a> and <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> have the most efficacy data and real-world experience. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Beta-lactamase inhibitor combinations'</a>.)  </p><p>If the beta-lactam beta-lactamase agents listed above are not available and there is a high suspicion for carbapenem-resistant gram-negative bacilli, then the addition of one of the following agents <strong>along with</strong> a carbapenem is a reasonable alternative: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">Tobramycin</a> 5 to 7 mg/kg IV daily  (<a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">figure 1</a>) </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">Colistin</a> 300mg colistin base activity (CBA) loading dose followed by 150 mg CBA every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">Aztreonam</a> 2 g IV every eight hours </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> 750 mg IV or orally daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 750 mg IV every 12 hours or 400mg orally every eight hours</p><p></p><p>A more detailed discussion of the efficacy and appropriateness of each agent is discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ceftazidime-avibactam</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a><strong> </strong>is a cephalosporin-beta-lactamase inhibitor combination approved by the US Food and Drug Administration (FDA) for treatment of nosocomial pneumonia [<a href="#rid43">43</a>]. We generally reserve use of ceftazidime-avibactam for patients with HAP or VAP who are known to be colonized by carbapenem-resistant Enterobacterales (CRE) because it has been shown to improve survival in these patients compared with other antibiotics. As an example, in a prospective, multicenter study of 137 patients with CRE infections, those who received ceftazidime-avibactam had a lower adjusted all-cause 30-day mortality compared with those who received <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> (9 versus 32 percent, absolute difference 23 percent, 95% CI 9-35) [<a href="#rid44">44</a>]. Other smaller observational studies comparing ceftazidime-avibactam with other antibiotics have shown similar trends in mortality [<a href="#rid45">45,46</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftazidime-avibactam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ceftolozane-tazobactam</strong> – <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a> is a cephalosporin-beta-lactamase inhibitor combination approved by the FDA for treatment of nosocomial pneumonia [<a href="#rid47">47,48</a>]. We generally reserve use of ceftolozane-tazobactam for patients with HAP or VAP who are known to be colonized by carbapenem-resistant <em>Pseudomonas aeruginosa</em> because this agent has greater in vitro activity and higher barrier to resistance against <em>P. aeruginosa</em> compared with <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> [<a href="#rid49">49,50</a>]. Ceftolozane-tazobactam has been shown to be more effective and safer than some of the older alternatives (eg, aminoglycosides, polymyxins) in the treatment of <em>P. aeruginosa</em> pneumonia. As an example, in a retrospective, multicenter cohort study of 200 patients with drug-resistant <em>P. aeruginosa</em>, patients who received ceftolozane-tazobactam were more likely to achieve clinical cure (81 versus 61 percent; OR 2.63, 95% CI 1.31-5.30) and have lower rates of acute kidney injury (AKI) (6 versus 34 percent; OR 0.08, 95% CI 0.03-0.22) compared with those who received aminoglycosides or <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftolozane-tazobactam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imipenem-cilastatin-relebactam</strong> – <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">Imipenem-cilastatin-relebactam</a> is a carbapenem-beta-lactamase inhibitor combination that restores <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>'s activity against some CRE and <em>Pseudomonas</em> isolates. It was approved for the treatment of hospital-acquired bacterial pneumonia (including VAP) following a randomized controlled trial that showed similar clinical response, mortality, and serious adverse event rates between imipenem-cilastatin-relebactam and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> [<a href="#rid52">52</a>]. We generally reserve the use of this agent to patients with history of CRE. In a randomized, double-blinded trial of 47 patients with imipenem-resistant pathogens, those who received imipenem-cilastatin-relebactam had higher rates of clinical response (71.4 versus 40 percent; absolute difference 26.3 percent, 90% CI 1.3-51.5), a trend towards lower mortality rate (9.5 versus 30 percent; absolute difference -17.3 percent, 90% CI -46.4 to 6.7), and nephrotoxicity (10.3 versus 56.3 percent; absolute difference -45.9 percent, 90% CI -69.1 to 18.4) compared with patients who received imipenem plus <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Imipenem-cilastatin-relebactam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meropenem-vaborbactam</strong> – <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">Meropenem-vaborbactam</a> is a carbapenem-beta-lactamase inhibitor that has been approved for the treatment of nosocomial pneumonia in Europe but not in the United States. In the United States, it is only approved for treatment of complicated urinary tract infections (UTIs) caused by Enterobacterales [<a href="#rid54">54</a>]. Meropenem-vaborbactam is not effective against carbapenem-resistant <em>P. aeruginosa</em>, <em>Acinetobacter baumannii</em>, or <em>Stenotrophomonas maltophilia</em>. Meropenem-vaborbactam is active against some CRE but clinical data on its performance in the treatment of HAP and VAP in particular are sparse [<a href="#rid55">55</a>]. A small observational study of 131 patients with CRE infections (37 percent with pneumonia) compared meropenem-vaborbactam to <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> and found similar 30-day and 90-day mortality as well as adverse event rates [<a href="#rid56">56,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Meropenem-vaborbactam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycosides</strong> – Because the aminoglycosides have poor lung penetration, increased risk of nephrotoxicity and ototoxicity, and poorer clinical response rates compared with other antibiotic classes, aminoglycosides are not recommended as monotherapy for gram-negative infections. However, rates of susceptibility among gram-negative bacilli are high, so we sometimes use them as part of the initial empiric regimen in patients with septic shock or rapidly progressive disease when there are little or no alternative options. Notably, since <em>P. aeruginosa</em> is a concern in patients with nvHAP/VAP, we prefer the use of <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> to other aminoglycosides as part of combination empiric therapy for nvHAP/VAP as it has greater intrinsic antipseudomonal activity. </p><p></p><p class="bulletIndent1">If aminoglycosides are used as part of a combination regimen and subsequent culture results indicate that the isolate is susceptible to a beta-lactam, the aminoglycoside should be discontinued. We will also discontinue the aminoglycoside after two or three days in patients who have improved clinically and in whom cultures are negative. In general, every effort should be made to minimize exposure to aminoglycosides since even very brief courses of aminoglycosides increase the risk of nephrotoxicity [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/483.html" rel="external">"Aminoglycosides", section on 'Toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymyxins</strong> – Addition of an alternative agent, such as intravenous <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> or <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a>, may be appropriate if highly resistant <em>Pseudomonas</em> spp, <em>Acinetobacter</em> spp, Enterobacterales (including <em>Klebsiella pneumoniae</em>) is suspected or established and newer beta-lactam beta-lactamase agents are not available [<a href="#rid59">59</a>]. Polymyxins are used rarely given their significant nephrotoxicity and should be avoided if alternative agents with adequate activity against gram-negative bacilli are available [<a href="#rid51">51,60</a>]. When they are required, an infectious disease physician and/or pharmacist with expertise using these agents should be consulted. Dosing recommendations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Nephrotoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aztreonam</strong> – Although the use of two beta-lactams is generally avoided, in the absence of other options, it is acceptable to use <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> as a second agent for gram-negative bacteria with another beta-lactam because it has different targets within the bacterial cell wall [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Monobactams (aztreonam)'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-pseudomonal fluoroquinolones </strong>–<strong> </strong>Although the<strong> </strong>ATS/IDSA guidelines recommend either an antipseudomonal fluoroquinolone or an aminoglycoside for the second agent for gram-negative bacilli when needed to increase the probability of active coverage and they also state that aminoglycosides should be avoided if alternative agents with adequate activity against gram-negative bacilli are available [<a href="#rid1">1</a>],<strong> </strong>we generally prefer an aminoglycoside over a fluoroquinolone for patients with severe disease if there is no concern for <em>Legionella, </em>as aminoglycosides are more likely to have in vitro activity against gram-negative bacilli in those with risk<strong> </strong>factors for resistance. When possible, clinicians should consult their local antibiogram to help determine whether similar resistance patterns exist at their institutions. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones"</a>.)</p><p></p><p>For patients with history of highly resistant or pan-resistant gram-negative bacilli, consultation with a specialist with expertise in antimicrobial management of antibiotic-resistant infections is recommended.</p><p class="headingAnchor" id="H4207647741"><span class="h4">Risk factors for MRSA</span><span class="headingEndMark"> — </span>Our approach to the treatment of HAP or VAP caused by MRSA is largely similar to the 2016 ATS/IDSA guidelines on HAP and VAP and the 2011 IDSA guidelines for the treatment of MRSA infections, which recommend either <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for infections suspected or proven to be due to MRSA [<a href="#rid1">1,61</a>].</p><p class="headingAnchor" id="H717245353"><span class="h5">Preferred agents</span><span class="headingEndMark"> — </span>For patients with VAP or nvHAP who have risk factors for MRSA, we suggest adding one of the following agents to the patient's empiric therapy regimen: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg IV every 12 hours, which may be administered orally when the patient is able to take oral medications. (See <a class="local">'Methicillin-resistant S. aureus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> dosing as summarized in the following table  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 4</a>). (See <a class="local">'Methicillin-resistant S. aureus'</a> below and  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a>.)</p><p></p><p>Adding an agent with MRSA activity to the treatment regimen allows for more flexibility in the choice of gram-negative agents since the gram-negative agent does not need to include activity against <em>S. aureus</em>. Potential regimens include any of the antibiotics mentioned above (eg, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>) as well as <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, or <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>. Among these agents, we generally prefer piperacillin-tazobactam, cefepime, or ceftazidime because they are more likely to have activity against gram-negative bacilli than the fluoroquinolones or aztreonam. The ATS/IDSA guidelines also include imipenem and meropenem as options, but we generally reserve these agents for situations in which they are required, such as in patients with a high likelihood of infection with an ESBL-producing gram-negative bacillus. </p><p>Because clinical outcomes appear to be similar for <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid62">62-64</a>], we select between these agents based on other factors such as renal function, monitoring convenience, potential drug interactions, blood cell counts, and quality of IV access (see <a class="local">'Methicillin-resistant S. aureus'</a> below). As examples, when all other factors are equal, we prefer linezolid to vancomycin in patients with limited IV access or difficulty achieving therapeutic serum concentrations of vancomycin and we prefer vancomycin to linezolid in patients receiving selective serotonin-reuptake inhibitors and for patients with cytopenias. </p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> and anti-pseudomonal beta-lactams, particularly <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, have been associated with acute kidney injury [<a href="#rid65">65,66</a>], although the risk is uncertain [<a href="#rid67">67</a>]. Patients receiving vancomycin with piperacillin-tazobactam should be closely monitored for renal dysfunction or alternative antibiotic combinations should be used. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults", section on 'Acute kidney injury'</a>.)</p><p class="headingAnchor" id="H1890300208"><span class="h5">Alternative options</span><span class="headingEndMark"> — </span>In the rare circumstance that <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> cannot be used, other alternatives include: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> 600 mg IV every 12 hours </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">Tedizolid</a> 200 mg IV once daily (may have lower clinical cure rates compared with <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> [<a href="#rid68">68</a>]; may be administered orally when the patient is able to take oral medications) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">Telavancin</a> 10 mg/kg IV every 24 hours (there are several boxed warnings that must be considered before choosing it) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> 500 mg IV every eight hours (use only for nvHAP [<a href="#rid69">69</a>]; not available in the United States) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (use only if local antibiogram shows most MRSA isolates are susceptible to clindamycin) </p><p></p><p>All efforts should be made to use the preferred agents against MRSA mentioned above (see <a class="local">'Preferred agents'</a> above). Alternative agents have less data supporting their use in nvHAP/VAP and may have less efficacy against MRSA and/or other significant adverse effects. (See <a class="local">'Methicillin-resistant S. aureus'</a> below.)</p><p class="headingAnchor" id="H364183904"><span class="h4">Risk factors for MRSA and MDR gram-negative bacilli</span><span class="headingEndMark"> — </span>For patients who have risk factors for both MRSA and MDR gram-negative bacilli (including <em>P. aeruginosa</em>), we suggest combining an agent against MRSA with an agent(s) against MDR gram-negative bacilli, as discussed above  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk factors for MRSA'</a> above and <a class="local">'Risk factors for MDR gram-negative bacilli'</a> above.)</p><p class="headingAnchor" id="H3878715346"><span class="h4">Increased risk of mortality in nvHAP</span><span class="headingEndMark"> — </span>For patients with nvHAP who have an increased risk of mortality from nvHAP (eg, need for intubation, septic shock), we suggest choosing the same empiric therapy regimen as for patients with VAP who have risk factors for both MRSA and MDR gram-negative bacilli  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk factors for MRSA and MDR gram-negative bacilli'</a> above.)</p><p class="headingAnchor" id="H1976715513"><span class="h1">TAILORING THERAPY</span><span class="headingEndMark"> — </span>All patients with non-ventilator-associated HAP (nvHAP) or ventilator-associated pneumonia (VAP) should be evaluated for clinical response and microbiologic results after initial empiric antimicrobial therapy. Reassessing a patient's status 48 to 72 hours after the initiation of therapy with consideration of discontinuing antibiotics or narrowing the regimen (de-escalating therapy) based upon appropriate culture results may reduce the selective pressure for antimicrobial resistance and appears to be safe [<a href="#rid70">70</a>]. (See <a class="local">'Antimicrobial resistance'</a> above.)</p><p class="headingAnchor" id="H1161662501"><span class="h2">Early de-escalation based on nasal MRSA swab results</span><span class="headingEndMark"> — </span>We send nasal methicillin-resistant <em>S. aureus</em> (MRSA) swabs on all patients with suspected nvHAP/VAP. If the nasal MRSA swab result (polymerase chain reaction [PCR] and/or culture) are negative, we suggest stopping anti-MRSA empiric therapy to reduce unnecessary antibiotic use. Observational studies [<a href="#rid71">71-73</a>] and at least one randomized trial [<a href="#rid74">74</a>] suggest that testing nasal swabs or bronchoalveolar lavage fluid for MRSA via culture or PCR can help decrease utilization of anti-MRSA therapy if negative results are used as a trigger to stop anti-MRSA treatment. In a randomized trial of 45 patients with suspected MRSA VAP who were randomized to have empiric anti-MRSA therapy discontinued based on rapid nasal MRSA swab results versus usual care, patients in the experimental group had lower in-hospital mortality, shorter duration of anti-MRSA treatment, and no differences in duration of mechanical ventilation, length of intensive care unit (ICU) or hospital stay, or adverse events [<a href="#rid74">74</a>]. Early discontinuation of MRSA coverage in patients with negative cultures and/or PCRs may be associated with better outcomes, including less renal failure and possibly lower mortality rates [<a href="#rid74">74,75</a>].</p><p class="headingAnchor" id="H1954587356"><span class="h2">No pathogen identified and clinically improving</span><span class="headingEndMark"> — </span>For patients who are clinically improving who do not have an identified pathogen, empiric treatment for MRSA<em>, Pseudomonas aeruginosa,</em> or multidrug-resistant (MDR) gram-negative bacilli can be discontinued if these organisms have not grown in culture from a high-quality sputum or bronchoalveolar lavage specimen within 48 to 72 hours.</p><p class="headingAnchor" id="H1982643843"><span class="h2">Pathogen identified and clinically improving</span><span class="headingEndMark"> — </span>For patients in whom a pathogen has been identified, the empiric regimen should be tailored to the pathogen's susceptibility pattern [<a href="#rid1">1,76,77</a>]. Tailoring antibiotic therapy when a pathogen has been identified and susceptibilities are known is generally very safe; there are no clear associations between tailoring antibiotics and increased mortality [<a href="#rid70">70,78-80</a>], recurrent pneumonia [<a href="#rid70">70,79</a>], or longer ICU admission [<a href="#rid70">70,80</a>]. </p><p>The approach to tailored therapy for MRSA and methicillin-susceptible Staphylococcus aureus (MSSA) is discussed below. (See <a class="local">'Methicillin-resistant S. aureus'</a> below and <a class="local">'Methicillin-susceptible S. aureus'</a> below.)</p><p>The approach to treatment of pneumonia caused by other pathogens is discussed in greater detail separately. </p><p class="headingAnchor" id="H7"><span class="h3">Methicillin-resistant S. aureus</span><span class="headingEndMark"> — </span>For patients with confirmed MRSA hospital-acquired (or nosocomial) pneumonia (HAP)/VAP, we suggest treatment with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>. The decision to use one or the other antibiotic depends on various factors, including the patient's other comorbidities, drug-drug interactions, risk for side effects, and cost. If neither vancomycin nor linezolid can be used, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> is an alternative, although it is not approved by the US Food and Drug Administration (FDA) for treatment of HAP/VAP and its efficacy in treating MRSA pneumonia is limited to case series [<a href="#rid81">81-83</a>]. Other anti-MRSA agents such as <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a> and <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> are not as effective in treating MRSA pneumonia and <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> have significant side effects which limit their use as first-line agents. <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is inactivated by lung surfactant and <strong>cannot</strong> be used to treat pneumonia. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linezolid</strong><strong> and </strong><strong>vancomycin</strong> – Several trials have compared <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for the treatment of HAP and VAP; clinical outcomes appear to be similar when comparing these two agents [<a href="#rid62">62-64</a>]. As an example, in a meta-analysis of nine randomized trials that compared linezolid to vancomycin for HAP, no differences in mortality, clinical response, or MRSA eradication were detected [<a href="#rid64">64</a>]. Linezolid was associated with a higher rate of gastrointestinal adverse effects, but there were no differences in rates of acute kidney injury (AKI), thrombocytopenia, or drug discontinuation due to adverse effects.</p><p></p><p class="bulletIndent1">Several trials included in this meta-analysis used lower doses for <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> than those recommended by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) [<a href="#rid1">1,61,84,85</a>], which may have resulted in lower efficacy rates for this agent. In one trial that did use optimal vancomycin dosing, clinical success rates were lower for vancomycin when compared with <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> in the per-protocol analysis (47 versus 58 percent; 11 percent absolute difference, 95% CI 0.5-22) [<a href="#rid86">86</a>]. However, higher rates of mechanical ventilation, renal dysfunction, and bacteremia in the vancomycin per-protocol group may account for this difference. No differences in all-cause 60-day mortality or overall adverse events were detected in this trial, although nephrotoxicity did occur more frequently with vancomycin than linezolid (18 versus 8 percent, p value not reported). Vancomycin failure might also be related to vancomycin minimum inhibitory concentrations (MICs). Pharmacokinetic and pharmacodynamic analyses suggest that lung vancomycin area under time-concentration curve to minimum inhibitory concentration ratio (AUC:MIC) &gt;400 may be difficult to achieve (particularly for isolates with MIC &gt;1) [<a href="#rid87">87-89</a>]. </p><p></p><p class="bulletIndent1">Some clinicians favor using an alternative to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for treatment of pneumonia caused by MRSA strains with vancomycin MICs ≥2 mcg/mLalthough there are no data demonstrating better outcomes with <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> or other alternatives compared to vancomycin in patients infected with MRSA with high vancomycin MICs. Cohort studies have reported worse outcomes in patients with HAP due to MRSA with higher MICs. In one prospective cohort of 95 patients, patients with MRSA isolates with MICs ≥2 mcg/mL had higher mortality rates than those with lower MICs (24 percent versus 10 percent) [<a href="#rid90">90</a>]. Another study of 158 intensive care patients reported a stepwise increase in mortality as the vancomycin MIC increased from 0.75 to 3 mcg/mL and was present even for strains within the susceptible range [<a href="#rid91">91</a>]. These findings are controversial, however, because studies of MSSA bacteremia have also correlated higher vancomycin MICs with higher mortality rates even though all patients were treated with beta-lactams [<a href="#rid92">92,93</a>]. These studies suggest that worse outcomes in patients with higher MICs may be due to clinical factors other than vancomycin failure alone. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – There has been interest in using other agents for the treatment of MRSA pneumonia, but <strong>none of the following agents are recommended as first-line options for MRSA pneumonia:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ceftaroline</strong> – <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> is a broad-spectrum cephalosporin with activity against MRSA and gram-negative pathogens (but not <em>P. aeruginosa</em>). It has been approved by the FDA for community-acquired pneumonia (CAP) but not for CAP caused by MRSA, nor for empiric treatment of HAP or VAP. Clinical success with ceftaroline use for the treatment of MRSA pneumonia has been reported in cases series but comparative studies are lacking [<a href="#rid81">81-83</a>]. (See  <a class="medical medical_review" href="/z/d/html/480.html" rel="external">"Cephalosporins", section on 'Fifth generation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tedizolid</strong> – <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">Tedizolid</a> is an antibiotic from the same family as <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> that inhibits bacterial protein synthesis. It is active against gram-positive bacteria including MRSA. In a randomized trial comparing tedizolid with linezolid, 726 ventilated patients with HAP or VAP suspected to be due to a gram-positive pathogen were randomized to tedizolid 200 mg IV daily for 7 days versus linezolid 600 mg IV twice a day for 10 days [<a href="#rid68">68</a>]. Adjunctive coverage for gram-negatives was permitted per clinicians' discretion. Tedizolid was found to be noninferior to linezolid with regard to all-cause mortality (28.1 versus 26.4 percent; 1.8 percent difference, 95% CI -8.2 to 4.7) but was associated with a lower rate of clinical cure (56.3 versus 63.9 percent; 7.6 percent difference, 97.5% CI -15.7 to 0.5). It is unclear whether the difference in clinical cure rates was due to the difference in drugs or difference in duration of treatment. Drug-related adverse events occurred in 8.1 percent of patients who received tedizolid versus 11.9 percent of those who received linezolid. Thrombocytopenia was more common in patients randomized to linezolid (38 versus 28 percent). (See  <a class="medical medical_review" href="/z/d/html/129184.html" rel="external">"Linezolid and tedizolid (oxazolidinones): An overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Telavancin</strong> – <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">Telavancin</a> is an antibiotic with activity against MRSA [<a href="#rid94">94</a>]. In 2013, telavancin was approved by the FDA for the treatment of HAP and VAP caused by <em>S. aureus</em> but not for other bacterial causes of HAP or VAP; it is recommended only when alternative agents cannot be used and should ideally be reserved for patients with normal renal function [<a href="#rid95">95</a>]. In patients with normal renal function, the dose of telavancin is 10 mg/kg IV every 24 hours.</p><p></p><p class="bulletIndent2">The FDA has included the following boxed warnings for <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> [<a href="#rid96">96</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with pre-existing moderate or severe renal impairment (creatinine clearance [CrCl] ≤50 mL/minute) who were treated with <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> for HAP or VAP had increased mortality compared with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. Use of telavancin in patients with pre-existing moderate or severe renal impairment (CrCl ≤50 mL/minute) should therefore be considered only when the potential benefit to the patient outweighs the potential risk.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>New-onset or worsening renal impairment has occurred in patients receiving <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>. Renal function should be monitored in all patients receiving telavancin.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adverse developmental outcomes were observed in three animal species at clinically relevant doses. These findings raise concerns about potential adverse developmental outcomes in humans. Women of childbearing potential should have a serum pregnancy test prior to administration of <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a>, and its use should be avoided during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.</p><p></p><p class="bulletIndent2">The data on the performance of <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> for HAP and VAP come from two randomized trials (the ATTAIN trials) comparing telavancin versus <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for hospitalized patients with HAP or VAP (29 percent had VAP) caused by gram-positive pathogens, particularly <em>S. aureus</em>. Pooled results from these two studies revealed no differences in overall cure rates or mortality in the vancomycin versus telavancin groups [<a href="#rid97">97</a>]. However, in a subgroup analysis of patients with renal impairment (CrCl &lt;50 mL/minute), cure rates were lower in patients who received telavancin when compared with vancomycin (47 versus 55 percent; 8 percent difference, 95% CI -17.5 to 1.9) [<a href="#rid98">98</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ceftobiprole</strong> – <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> is a broad-spectrum cephalosporin with activity against a broad range of gram-positive bacteria including MRSA and penicillin- and ceftriaxone-resistant pneumococci, as well as gram-negative bacteria. It has not been approved by the FDA, but it has been approved in Europe and Canada for treatment of HAP and CAP but not VAP. In a trial of patients with HAP, 781 patients with HAP (including 210 with VAP) were randomly assigned to receive either ceftobiprole or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> plus <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> [<a href="#rid69">69</a>]. In the intention-to-treat population, overall cure rates for ceftobiprole versus linezolid plus ceftazidime were similar (50 versus 53 percent). Cure rates in HAP (excluding VAP) patients were also similar (60 versus 59 percent). However, cure rates in VAP patients were substantially lower in those who received ceftobiprole (23 versus 37 percent). Microbiologic eradication rates in HAP (excluding VAP) patients were 63 versus 68 percent (microbiologically evaluable [ME], 95% CI -16.7 to 7.6) and in VAP patients were 30 versus 50 percent (ME, 95% CI -38.8 to -0.4) [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/480.html" rel="external">"Cephalosporins", section on 'Fifth generation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tigecycline</strong> – <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> is a broad-spectrum antibiotic with activity against MRSA. It has been approved by the FDA for skin and skin structure infections and intra-abdominal infections caused by MRSA. It has also been approved for CAP but <strong>not</strong> for CAP caused by MRSA or for HAP or VAP. In 2010, the FDA issued a safety announcement regarding an increased mortality risk associated with the use of tigecycline compared with other drugs observed in a pooled analysis of 13 trials [<a href="#rid100">100</a>]. The increased risk was seen most clearly in patients treated for HAP, particularly VAP. In 2013, the FDA added a boxed warning in reaction to an additional analysis showing an increased risk of death associated with tigecycline use [<a href="#rid101">101</a>]. The boxed warning states that tigecycline should be reserved for use in situations when alternative agents are not suitable. In an analysis of 10 trials conducted for FDA-approved uses (CAP, complicated skin and skin structure infections, complicated intra-abdominal infections), tigecycline was associated with increased mortality compared with other antibacterial agents (2.5 versus 1.8 percent, adjusted risk difference 0.6 percent, 95% CI 0.0-1.2). Most deaths resulted from worsening infections, complications of infection, or underlying comorbidities. Randomized trials of patients with HAP have reported similar results [<a href="#rid102">102,103</a>]. (See  <a class="medical medical_review" href="/z/d/html/494.html" rel="external">"Tetracyclines"</a>.)</p><p></p><p class="headingAnchor" id="H423214193"><span class="h3">Methicillin-susceptible S. aureus</span><span class="headingEndMark"> — </span>If sputum or bronchoalveolar lavage (BAL) culture reveals MSSA, empiric therapy for MRSA should be replaced with <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> (2 g IV every four hours), <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> (2 g IV every four hours), or <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (2 g IV every eight hours) [<a href="#rid1">1</a>]. Of these, cefazolin is generally preferred since it is associated with fewer adverse effects (renal dysfunction, hepatotoxicity) compared to oxacillin or nafcillin. If no other organisms have been isolated then monotherapy with one of these agents is adequate. If culture data suggests a polymicrobial infection, then one can choose either monotherapy with an agent that covers both MSSA and gram-negatives (eg, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) or the combination of an anti-gram-positive agent and an anti-gram-negative agent tailored to the recovered pathogens' antibiotic susceptibility profiles. In patients with concurrent MSSA bacteremia, the inclusion of a directed-MSSA agent (eg, cefazolin, oxacillin) is preferred over a broader-spectrum beta-lactam (see  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Methicillin-sensitive S. aureus'</a>). <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">Ceftazidime</a> has limited anti-gram-positive activity and should not be used in isolation for patients with MSSA pneumonia. </p><p class="headingAnchor" id="H2366713567"><span class="h3">Streptococci and other gram-positive pathogens</span><span class="headingEndMark"> — </span>For HAP/VAP caused by streptococci and other gram-positive pathogens (eg, <em>S. lugdunensis</em>), we tailor therapy to the pathogen isolated from culture. Although streptococci are susceptible to many different antibiotic classes, beta-lactams are preferred, especially penicillin and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>. (See  <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3178.html" rel="external">"Infections due to the <i>Streptococcus anginosus </i>(<i>Streptococcus milleri</i>) group", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/3171.html" rel="external">"Group B streptococcal infections in nonpregnant adults", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections", section on 'Antibiotic agents'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Gram-negative pathogens</span><span class="headingEndMark"> — </span>For HAP/VAP caused by non-extended-spectrum beta-lactamase (ESBL) and non-carbapenem-resistant Enterobacterales (CRE) isolates, we favor choosing an antibiotic with the narrowest spectrum of activity that will be effective against the gram-negative pathogen based on its susceptibility profile. Common antibiotic selections include <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>. Carbapenems are usually not indicated for pneumonia caused by highly susceptible gram-negative pathogens unless there is concern for allergies. (See <a class="local">'Anaerobes'</a> below and <a class="local">'Allergy to penicillins or cephalosporins'</a> below.)</p><p>The approach to treatment of pneumonia caused by <em>Pseudomonas aeruginosa</em>, ESBL and carbapenemase-producing gram-negative bacilli, <em>Acinetobacter</em> spp, <em>Stenotrophomonas maltophilia</em>, <em>Haemophilus influenzae</em>, and <em>Legionella</em> spp is discussed in greater detail separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases", section on 'Treatment options'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Approach to treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">"Acinetobacter infection: Treatment and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7025.html" rel="external">"Treatment and prevention of <i>Legionella</i> infection", section on 'Treatment of Legionnaires' disease (Legionella pneumonia)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>", section on 'Directed treatment'</a>.)</p><p></p><p class="headingAnchor" id="H3686846924"><span class="h3">Anaerobes</span><span class="headingEndMark"> — </span>nvHAP/VAP caused by anaerobes is uncommon. When it does occur, it generally is caused by aspiration of oral anaerobic flora. The presence of gut anaerobic pathogens in respiratory specimens, such as <em>Bacteroides fragilis</em>, should prompt suspicion and evaluation for intestinal pathology. (See  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5520.html" rel="external">"Anaerobic bacterial infections", section on 'Pleuropulmonary infections'</a>.)</p><p class="headingAnchor" id="H1148790827"><span class="h2">No clinical improvement after 48 to 72 hours</span><span class="headingEndMark"> — </span>Patients who have not improved within 72 hours of starting empiric antibiotics or appropriate antibiotics for the causative pathogen should be evaluated for complications (eg, empyema, lung abscess), other sites of infection, and alternate diagnoses (eg, thromboembolic disease, pulmonary edema, malignancy, hypersensitivity reaction, etc). </p><p>If the diagnosis of bacterial pneumonia appears certain, there is no evidence of a pyogenic complication that requires drainage (eg, empyema, lung abscess), no evidence of untreated infections elsewhere in the body, and the patient has risk factors for drug-resistant pathogens (eg, prolonged hospitalization, recent exposure to multiple antibiotics), additional diagnostic pulmonary cultures should be obtained and the empiric regimen can be expanded to cover additional resistant organisms.</p><p>In patients with progressive HAP despite broad-spectrum antibiotic use, other potential hospital-acquired infections such as respiratory viral infections or <em>Legionella</em> should be considered. During outbreaks of highly drug-resistant organisms, such as <em>Acinetobacter </em>species or <em>Stenotrophomonas</em> species, including an antibiotic that targets these organisms in the empiric treatment regimen may be warranted. In immunocompromised patients, the differential diagnosis should be broad and include fungal, viral, parasitic, and less common bacterial pathogens. (See  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a>.)</p><p class="headingAnchor" id="H3287760033"><span class="h1">DURATION</span><span class="headingEndMark"> — </span>We suggest treating most patients with non-ventilator-associated HAP (nvHAP) or ventilator-associated pneumonia (VAP) for seven days, in agreement with the 2016 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines and the combined 2017 European and Latin American guidelines on HAP and VAP [<a href="#rid1">1,3</a>]. Seven days appears to be as effective as longer durations in most circumstances and may reduce the emergence of resistant organisms [<a href="#rid1">1,5</a>].</p><p>For selected patients with metastatic infection, gram-positive bacteremia, slow response to therapy, immunocompromise, and pyogenic complications such as empyema or lung abscess, the duration of therapy should be individualized and courses longer than seven days may be warranted. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Completing antibiotic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia", section on 'Directed antimicrobial therapy'</a>.)</p><p>Monitoring serial procalcitonin levels can help guide the decision to discontinue antibiotics. While the optimal approach to using procalcitonin in patients with hospital-acquired (or nosocomial) pneumonia (HAP) or VAP has not been determined, a low or declining procalcitonin level (eg, &lt;0.25 ng/mL or ≥80 percent decrease from peak) in a patient who has clinically improved on antibiotics provides additional reassurance that antibiotics can be safely stopped [<a href="#rid104">104-111</a>]. (See  <a class="medical medical_review" href="/z/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Ventilator-associated pneumonia'</a>.)</p><p>A seven-day course of antimicrobial therapy is supported by two meta-analyses of up to six randomized trials evaluating over 1000 patients with HAP or VAP, in which short courses (7 to 8 days) of therapy were as effective as longer courses (10 to 15 days) [<a href="#rid1">1,112,113</a>]. In subgroup analysis of one of the meta-analyses [<a href="#rid112">112</a>], a higher rate of recurrent pneumonia was observed in patients with pneumonia caused by nonfermenting gram-negative rods, such as <em>P. aeruginosa</em>, who received shorter courses of therapy. This finding was primarily driven by a single large trial that used a microbiologic definition of pneumonia [<a href="#rid114">114</a>]; hence, this finding may have indicated microbiologic persistence rather than clinical failure. No differences in ventilator-free days, organ failure-free days, length of stay, or mortality were detected in patients with nonfermenting gram-negative bacillus infections randomized to short versus long courses [<a href="#rid1">1,112,115</a>]. Another multicenter, randomized trial of 186 patients with VAP due to <em>P. aeruginosa</em> demonstrated similar findings [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia", section on 'Duration of therapy'</a>.)</p><p>Although a retrospective cohort study suggested that patients with suspected VAP who have stable and minimal ventilator settings (positive-end expiratory pressure &lt;5 cm H<sub>2</sub>O and FiO<sub>2</sub> ≤40 percent) have similar outcomes whether they are treated with ≤3 days or &gt;3 days of antibiotics [<a href="#rid117">117</a>], these observations must be confirmed in a randomized trial before this strategy can be broadly applied.</p><p class="headingAnchor" id="H562839269"><span class="h1">CONVERSION TO ORAL ANTIBIOTICS</span><span class="headingEndMark"> — </span>Generally, patients can be switched to oral therapy when they are hemodynamically stable, clinically improving, and able to tolerate oral medications [<a href="#rid118">118</a>]. If a pathogen has been identified, the choice of antibiotic for oral therapy should be based on the organism's susceptibility pattern. If a pathogen has not been identified, the oral antibiotic selected should be based on an appropriate de-escalation approach and generally can exclude coverage for MRSA and <em>P. aeruginosa</em>. All oral antibiotics selected for the treatment of pneumonia should have good lung penetration. </p><p class="headingAnchor" id="H1142612322"><span class="h1">OTHER MANAGEMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H811835002"><span class="h2">Prolonged infusions of beta-lactams</span><span class="headingEndMark"> — </span>We favor prolonged infusions of beta-lactams for empiric and targeted therapy of gram-negative bacilli with at least one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In critically ill patients </p><p class="bulletIndent1"><span class="glyph">●</span>Elevated but susceptible minimal inhibitory concentrations (MICs) to the chosen agent  (<a class="graphic graphic_table graphicRef99434" href="/z/d/graphic/99434.html" rel="external">table 5</a>) </p><p></p><p>Suitable agents for prolonged infusions include <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, and <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>. The decision to use this dosing strategy should also take into account logistical issues such as staffing or intravenous (IV) access availability.</p><p>Beta-lactam antibiotics demonstrate a time-dependent effect on bacterial eradication. Prolonged infusions achieve pharmacodynamic efficacy targets defined for beta-lactam antibiotics more effectively than traditional, short, intermittent infusions (eg, administered over 30 minutes). A prolonged infusion may therefore improve microbiologic and clinical cure, especially for pathogens with high MICs. Prolonged infusion for intravenous beta-lactams may include either a continuous infusion (over the entire dosing interval) or an extended infusion (over three to four hours).</p><p>Pharmacologic and clinical data indicate that patients who have an elevated risk of drug-resistant pathogens or who are critically ill in the setting of a severe infection are most likely to benefit from prolonged infusions. In a patient-level meta-analysis of 22 randomized trials including 1876 patients that compared prolonged versus rapid infusions of antipseudomonal beta-lactams in patients with sepsis, mortality was 30 percent lower in patients receiving prolonged infusions (risk ratio [RR] 0.70, 95% CI 0.56-0.87) [<a href="#rid119">119</a>]. Further discussion of prolonged infusions of beta-lactams is provided separately. (See  <a class="medical medical_review" href="/z/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p>The traditional intermittent dosing of each agent for hospital-acquired (or nosocomial) pneumonia (HAP) is described in this topic, but we favor prolonged infusions of antipseudomonal beta-lactams to optimize pharmacodynamics, especially in critically ill patients with infections caused by gram-negative bacilli and for patients with infections caused by gram-negative bacilli that have elevated but susceptible MICs to the chosen agent  (<a class="graphic graphic_table graphicRef99434" href="/z/d/graphic/99434.html" rel="external">table 5</a>). </p><p class="headingAnchor" id="H1459068110"><span class="h2">Aerosolized antibiotics</span><span class="headingEndMark"> — </span>Knowledge on the most appropriate use of aerosolized antibiotics is evolving. We do not use aerosolized antibiotics as part of empiric therapy for the treatment of non-ventilator-associated HAP (nvHAP)/ventilator-associated pneumonia (VAP). Aerosolized <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a>, polymyxin, or aminoglycosides can be used as adjunctive therapy (in combination with IV antibiotics) in patients with VAP or HAP caused by multidrug-resistant (MDR) gram-negative bacilli, such as <em>A. baumannii or P. aeruginosa</em> [<a href="#rid1">1,120-126</a>]. (See  <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">"Acinetobacter infection: Treatment and prevention", section on 'Pneumonia'</a> and  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia", section on 'Inhaled antibiotics for selected patients'</a>.) </p><p>Aerosolization may increase antibiotic concentrations at the site of infection and may be particularly useful for treatment of organisms that have high MICs to systemic antimicrobial agents [<a href="#rid127">127</a>]. However, the evidence supporting use of aerosolized antibiotics is not strong [<a href="#rid128">128-130</a>] and administration can be associated with adverse effects, particularly in hypoxemic patients [<a href="#rid128">128,129</a>]. As an example, in a meta-analysis of 13 randomized trials [<a href="#rid131">131</a>], adding aerosolized <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> to IV antibiotics for gram-negative pneumonia versus treating with IV antibiotics alone was associated with higher rates of clinical cure in unblinded studies (9 studies, 700 patients; risk ratio 1.46, 95% CI 1.31-1.63) but not in blinded studies (4 studies, 750 patients; risk ratio 1.01, 95% CI 0.89-1.16). Similarly, adding aerosolized amikacin to IV treatment versus IV treatment alone was associated with no difference in duration of mechanical ventilation, intensive care unit (ICU) length-of-stay, or mortality. However, adjunctive aerosolized amikacin was associated with more bronchospasm, sometimes with hypoxemia (6.4 versus 2.4 percent of patients; risk ratio 2.55, 95% CI 1.40-4.66). There was no difference in the rate of renal dysfunction between treatment strategies. Other studies have reported occasional episodes of cardiac arrest when aerosolizing antibiotics due to obstruction of the ventilator circuit expiratory filter [<a href="#rid120">120,122</a>].</p><p>The addition of aerosolized <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> to intravenous colistin is rarely used with the advent of newer beta-lactam agents [<a href="#rid132">132,133</a>]. In a meta-analysis of three randomized trials including over 300 patients, addition of aerosolized colistin was associated with better microbiologic eradication rates but higher rates of bronchospasm [<a href="#rid133">133</a>]. Clinical response was similar between those who received IV monotherapy and those with aerosolized and intravenous colistin (66 versus 62 percent; OR 1.28, 95% CI 0.56-2.93). </p><p class="headingAnchor" id="H2379193204"><span class="h2">Allergy to penicillins or cephalosporins</span><span class="headingEndMark"> — </span>For patients who are allergic to penicillins or cephalosporins, the type and severity of reaction should be assessed. The great majority of patients who are allergic to penicillin can receive third-generation (and higher) cephalosporins or carbapenems using a simple graded challenge (1/10 dose followed by a one-hour period of observation; if no symptoms, give the full dose followed by another hour of observation). If a skin test for penicillin allergy is positive or if there is significant concern to warrant avoidance of a cephalosporin or carbapenem (IgE-mediated reaction), <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every eight hours) is a reasonable alternative. It is important to note that aztreonam does not provide activity against gram-positive bacteria like <em>S. aureus</em>. When this agent is used for empiric therapy, an additional agent with activity against <em>S. aureus</em> (eg, another beta-lactam, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>) should also be used.</p><p>Approaches to the choice of antibiotics for patients with penicillin  (<a class="graphic graphic_algorithm graphicRef112936" href="/z/d/graphic/112936.html" rel="external">algorithm 3</a>) and cephalosporin  (<a class="graphic graphic_algorithm graphicRef122624" href="/z/d/graphic/122624.html" rel="external">algorithm 4</a> and <a class="graphic graphic_algorithm graphicRef122623" href="/z/d/graphic/122623.html" rel="external">algorithm 5</a>) allergies can be found in the algorithms. List of cephalosporins with different side chains is listed in the table  (<a class="graphic graphic_table graphicRef122931" href="/z/d/graphic/122931.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/z/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Despite high absolute mortality rates in hospital-acquired (or nosocomial) pneumonia (HAP) patients, the mortality attributable to the infection is difficult to gauge. Many studies report that HAP is associated with high crude mortality rates. However, many of these critically ill patients die from their underlying disease and not from pneumonia. While crude all-cause mortality associated with ventilator-associated pneumonia (VAP) has ranged from 20 to 50 percent in different studies [<a href="#rid1">1</a>], a meta-analysis of randomized trials of VAP prevention estimated the attributable mortality at 13 percent [<a href="#rid134">134</a>]. Another study estimated that eliminating VAP would lead to a relative decrease in 60-day intensive care unit mortality of 3.6 percent [<a href="#rid135">135</a>]. Similarly, a large study of non-ventilator-associated HAP (nvHAP) across 284 United States hospitals estimated that eliminating nvHAP would decrease overall hospital mortality rates by 7.3 percent [<a href="#rid136">136</a>].</p><p>Variables associated with increased mortality include [<a href="#rid1">1,137-146</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serious illness at the time of diagnosis (eg, high Acute Physiology and Chronic Health Evaluation [APACHE] score, shock, coma, respiratory failure, acute respiratory distress syndrome [ARDS])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe underlying comorbid disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection caused by an organism associated with multidrug resistance (eg, <em>P. aeruginosa</em>, <em>Acinetobacter</em> spp, and Enterobacteriaceae, including <em>K. pneumoniae</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multilobar, cavitating, or rapidly progressive infiltrates on lung imaging</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delay in the institution of effective antimicrobial therapy</p><p></p><p class="headingAnchor" id="H1805039807"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109779.html" rel="external">"Society guideline links: Hospital-acquired pneumonia and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H9523887"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83154.html" rel="external">"Patient education: Hospital-acquired pneumonia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Pneumonia is frequently categorized based on site of acquisition  (<a class="graphic graphic_table graphicRef130821" href="/z/d/graphic/130821.html" rel="external">table 1</a>). (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying risk factors for MDR</strong> <strong>pathogens and mortality in VAP and nvHAP</strong> – Risk factors for multidrug-resistant (MDR) pathogens and/or mortality in patients with ventilator-associated pneumonia (VAP)  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a>) and non-ventilator-associated HAP (nvHAP)  (<a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>) are listed in the tables. (See <a class="local">'Identifying risk factors for MDR pathogens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing an empiric regimen</strong> – Empiric regimens for VAP  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a>) and nvHAP  (<a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>) are outlined in the algorithms. The choice of the antibiotic treatment regimen for hospital-acquired (or nosocomial) pneumonia (HAP) should be informed by the patient's recent antibiotic therapy (if any), the resident flora and resistance rates in the hospital or intensive care unit (ICU), the presence of underlying diseases, severity of illness, available culture data (including the patient's past microbiology data) and Gram stain, and additional risk factors for MDR pathogens. Further considerations include potential toxicities, potential drug interactions, cost, availability, and clinician familiarity with proposed medications. (See <a class="local">'Choosing an empiric regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No risk factors present</strong> – For patients with nvHAP/VAP who have <strong>no</strong> known risk factors for MDR pathogens  (<a class="graphic graphic_table graphicRef109530" href="/z/d/graphic/109530.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef109531" href="/z/d/graphic/109531.html" rel="external">table 3</a>) and no increased mortality risk for those with nvHAP, we suggest a regimen that has activity against <em>Pseudomonas</em>, other gram-negative bacilli, and methicillin-susceptible <em>S. aureus </em>(MSSA), such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> is a reasonable alternative if there is a high suspicion for <em>Legionella</em> spp pneumonia and local resistance rates of <em>S. aureus</em>, <em>P. aeruginosa</em>, and other gram-negative bacilli to fluoroquinolones are low. (See <a class="local">'No risk factors present'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors for MDR gram-negative bacilli</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No history of carbapenem-resistant pathogens</strong> – For patients with VAP or nvHAP who have risk factors for MDR gram-negative bacilli and no history of carbapenem-resistant pathogens, we suggest a carbapenem (eg, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'No history of carbapenem-resistant pathogens'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>History of carbapenem-resistant pathogens present</strong> – For patients with high concern for or with prior respiratory culture data demonstrating carbapenem-resistant pathogens, we suggest empiric monotherapy with one of the newer beta-lactam beta-lactamase inhibitors rather than combination therapy with two different agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Appropriate beta-lactam beta-lactamase inhibitors include <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a>, and <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>. Selection among these antibiotics is guided by availability and the patient's prior culture and susceptibility data, when available. </p><p></p><p class="bulletIndent3">If the beta-lactam beta-lactamase agents mentioned above are not available and there is a high suspicion for carbapenem-resistant gram-negative bacilli, then the addition of <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, an anti-pseudomonal fluoroquinolone, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, or col<strong>istin along with</strong> a carbapenem is a reasonable alternative based on previous culture susceptibility patterns. (See <a class="local">'History of carbapenem-resistant pathogens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors for MRSA</strong> – For patients with VAP or nvHAP who have risk factors for methicillin-resistant <em>S. aureus</em> (MRSA), we recommend adding <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> to the patient's empiric therapy regimen (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Risk factors for MRSA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors for MRSA and MDR gram-negative bacilli</strong> – For patients who have risk factors for both MRSA and MDR gram-negative bacilli (including <em>P. aeruginosa</em>), we combine an agent against MRSA with an agent(s) against MDR gram-negative bacilli, as discussed above  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk factors for MRSA'</a> above and <a class="local">'Risk factors for MDR gram-negative bacilli'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased</strong> <strong>risk of mortality in nvHAP</strong> – For patients with nvHAP who have an increased risk of mortality, we choose the same empiric therapy regimen as for patients with VAP who have risk factors for both MRSA and MDR gram-negative bacilli  (<a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk factors for MRSA and MDR gram-negative bacilli'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tailoring therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early de-escalation based on nasal MRSA swab</strong> – We send nasal MRSA swabs on all patients with suspected MRSA nvHAP/VAP. If the nasal MRSA swab result (polymerase chain reaction [PCR] and/or culture) is negative, we suggest stopping anti-MRSA empiric therapy to reduce unnecessary antibiotic use (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Early de-escalation based on nasal MRSA swab results'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No pathogen identified and clinically improving</strong> – For patients who are clinically improving who do not have an identified pathogen, empiric treatment for MRSA<em>, Pseudomonas aeruginosa,</em> or MDR gram-negative bacilli can be discontinued if these organisms have not grown in culture from a high-quality sputum specimen within 48 to 72 hours. (See <a class="local">'No pathogen identified and clinically improving'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogen identified and clinically improving</strong> – For patients in whom a pathogen has been identified, the empiric regimen should be tailored to the pathogen's susceptibility pattern. (See <a class="local">'Pathogen identified and clinically improving'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No clinical improvement after 48 to 72 hours</strong> – Patients who have not improved within 72 hours of starting empiric antibiotics or appropriate antibiotics for the causative pathogen should be evaluated for complications (eg, empyema, lung abscess), other sites of infection, and alternate diagnoses (eg, thromboembolic disease, pulmonary edema, malignancy, hypersensitivity reaction, etc). If further diagnostic evaluation is unrevealing, additional diagnostic pulmonary cultures should be obtained and the empiric regimen can be expanded to cover additional resistant organisms (eg, <em>Legionella</em> <em>pneumoniae</em>, <em>Stenotrophomonas</em> <em>maltophilia</em>, <em>Acinetobacter</em> spp). (See <a class="local">'No clinical improvement after 48 to 72 hours'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration and conversion to oral antibiotics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest treating most patients with HAP or VAP for seven days (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For selected patients with metastatic infection, gram-positive bacteremia, slow response to therapy, immunocompromise, and pyogenic complications such as empyema or lung abscess, the duration of therapy should be individualized and courses longer than seven days may be warranted. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Generally, patients can be switched to oral therapy when they are hemodynamically stable, clinically improving, and able to tolerate oral medications. (See <a class="local">'Conversion to oral antibiotics'</a> above.)</p><p></p><p class="headingAnchor" id="H1842039796"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.</a></li><li><a class="nounderline abstract_t">Kollef MH. Health care-associated pneumonia: perception versus reality. Clin Infect Dis 2009; 49:1875.</a></li><li><a class="nounderline abstract_t">Murri R, De Pascale G. The challenge of identifying resistant-organism pneumonia in the emergency department: still navigating on the erie canal? Clin Infect Dis 2012; 54:199.</a></li><li><a class="nounderline abstract_t">Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012; 25:166.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011; 53:107.</a></li><li><a class="nounderline abstract_t">Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am 2013; 27:1.</a></li><li><a class="nounderline abstract_t">Ma HM, Wah JL, Woo J. Should nursing home-acquired pneumonia be treated as nosocomial pneumonia? J Am Med Dir Assoc 2012; 13:727.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330.</a></li><li><a class="nounderline abstract_t">Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54:193.</a></li><li><a class="nounderline abstract_t">Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score. Antimicrob Agents Chemother 2016; 60:2652.</a></li><li><a class="nounderline abstract_t">Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268.</a></li><li><a class="nounderline abstract_t">Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787.</a></li><li><a class="nounderline abstract_t">Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621.</a></li><li><a class="nounderline abstract_t">Baker AM, Meredith JW, Chang M, et al. Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients. J Bronchology Interv Pulmonol 2003; 10:7.</a></li><li><a class="nounderline abstract_t">Hranjec T, Rosenberger LH, Swenson B, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 2012; 12:774.</a></li><li><a class="nounderline abstract_t">O'Dell JC, Halimeh BN, Johnston J, et al. Antibiotic Initiation Timing and Mortality in Trauma Patients With Ventilator-Associated Pneumonia. Am Surg 2023; 89:4740.</a></li><li><a class="nounderline abstract_t">Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 2008; 23:91.</a></li><li><a class="nounderline abstract_t">Muscedere JG, Shorr AF, Jiang X, et al. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care 2012; 27:322.e7.</a></li><li><a class="nounderline abstract_t">Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851.</a></li><li><a class="nounderline abstract_t">Swanson JM, Wells DL. Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia. Antibiotics (Basel) 2013; 2:339.</a></li><li><a class="nounderline abstract_t">Rhee C, Kadri SS, Dekker JP, et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA Netw Open 2020; 3:e202899.</a></li><li><a class="nounderline abstract_t">Arulkumaran N, Routledge M, Schlebusch S, et al. Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med 2020; 46:225.</a></li><li><a class="nounderline abstract_t">Darie AM, Khanna N, Jahn K, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med 2022; 10:877.</a></li><li><a class="nounderline abstract_t">Jones M, Jernigan JA, Evans ME, et al. Vital Signs: Trends in Staphylococcus aureus Infections in Veterans Affairs Medical Centers - United States, 2005-2017. MMWR Morb Mortal Wkly Rep 2019; 68:220.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med 2020; 382:1309.</a></li><li><a class="nounderline abstract_t">Vincent JL, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020; 323:1478.</a></li><li><a class="nounderline abstract_t">Maruyama T, Fujisawa T, Okuno M, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013; 57:1373.</a></li><li><a class="nounderline abstract_t">Yoshimura J, Yamakawa K, Ohta Y, et al. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial. JAMA Netw Open 2022; 5:e226136.</a></li><li><a class="nounderline abstract_t">Nowak MA, Nelson RE, Breidenbach JL, et al. Clinical and economic outcomes of a prospective antimicrobial stewardship program. Am J Health Syst Pharm 2012; 69:1500.</a></li><li><a class="nounderline abstract_t">Dortch MJ, Fleming SB, Kauffmann RM, et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt) 2011; 12:15.</a></li><li><a class="nounderline abstract_t">Lew KY, Ng TM, Tan M, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother 2015; 70:1219.</a></li><li><a class="nounderline abstract_t">Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother 2010; 65:1062.</a></li><li><a class="nounderline abstract_t">Goff DA, File TM Jr. The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections. Infect Dis Clin North Am 2016; 30:539.</a></li><li><a class="nounderline abstract_t">Kohlmann R, Gatermann SG. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data--The Influence of Different Parameters in a Routine Clinical Microbiology Laboratory. PLoS One 2016; 11:e0147965.</a></li><li><a class="nounderline abstract_t">Randhawa V, Sarwar S, Walker S, et al. Weighted-incidence syndromic combination antibiograms to guide empiric treatment of critical care infections: a retrospective cohort study. Crit Care 2014; 18:R112.</a></li><li><a class="nounderline abstract_t">Dragan V, Wei Y, Elligsen M, et al. Prophylactic Antimicrobial Therapy for Acute Aspiration Pneumonitis. Clin Infect Dis 2018; 67:513.</a></li><li><a class="nounderline abstract_t">Shorr AF, Ilges DT, Micek ST, Kollef MH. The importance of viruses in ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2023; 44:1137.</a></li><li class="breakAll">Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0. https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed on June 27, 2023).</li><li><a class="nounderline abstract_t">Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018; 320:984.</a></li><li><a class="nounderline abstract_t">Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285.</a></li><li><a class="nounderline abstract_t">van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163.</a></li><li><a class="nounderline abstract_t">Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019; 68:355.</a></li><li><a class="nounderline abstract_t">Alraddadi BM, Saeedi M, Qutub M, et al. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis 2019; 19:772.</a></li><li class="breakAll">ZERBAXA prescribing information - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206829s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206829s008lbl.pdf (Accessed on June 28, 2019).</li><li><a class="nounderline abstract_t">Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299.</a></li><li><a class="nounderline abstract_t">Grupper M, Sutherland C, Nicolau DP. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020; 71:304.</a></li><li><a class="nounderline abstract_t">Titov I, Wunderink RG, Roquilly A, et al. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 2021; 73:e4539.</a></li><li><a class="nounderline abstract_t">Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020; 70:1799.</a></li><li class="breakAll">US Food and Drug Administration. Vabomere. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf (Accessed on July 18, 2018).</li><li><a class="nounderline abstract_t">Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7:439.</a></li><li><a class="nounderline abstract_t">Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23:1072.</a></li><li><a class="nounderline abstract_t">Ong DSY, Frencken JF, Klein Klouwenberg PMC, et al. Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study. Clin Infect Dis 2017; 64:1731.</a></li><li><a class="nounderline abstract_t">Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670.</a></li><li><a class="nounderline abstract_t">Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care 2019; 23:383.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 2013; 32:1121.</a></li><li><a class="nounderline abstract_t">Wang Y, Zou Y, Xie J, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol 2015; 71:107.</a></li><li><a class="nounderline abstract_t">Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013; 3:e003912.</a></li><li><a class="nounderline abstract_t">Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med 2018; 46:12.</a></li><li><a class="nounderline abstract_t">Bellos I, Karageorgiou V, Pergialiotis V, Perrea DN. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect 2020; 26:696.</a></li><li><a class="nounderline abstract_t">Qian ET, Casey JD, Wright A, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA 2023; 330:1557.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Roquilly A, Croce M, et al. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Clin Infect Dis 2021; 73:e710.</a></li><li><a class="nounderline abstract_t">Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; 59:51.</a></li><li><a class="nounderline abstract_t">De Bus L, Depuydt P, Steen J, et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Med 2020; 46:1404.</a></li><li><a class="nounderline abstract_t">Boyce JM, Pop OF, Abreu-Lanfranco O, et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013; 57:1163.</a></li><li><a class="nounderline abstract_t">Baby N, Faust AC, Smith T, et al. Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Pickens CI, Qi C, Postelnick M, et al. Association between a rapid diagnostic test to detect methicillin-resistant Staphylococcus Aureus pneumonia and decreased vancomycin use in a medical intensive care unit over a 30-month period. Infect Control Hosp Epidemiol 2021; 42:1385.</a></li><li><a class="nounderline abstract_t">Paonessa JR, Shah RD, Pickens CI, et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL: A Pilot Randomized Controlled Trial. Chest 2019; 155:999.</a></li><li><a class="nounderline abstract_t">Jones BE, Ying J, Stevens V, et al. Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med 2020; 180:552.</a></li><li><a class="nounderline abstract_t">Ewig S. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis 2011; 11:155.</a></li><li><a class="nounderline abstract_t">Niederman MS, Soulountsi V. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? Clin Chest Med 2011; 32:517.</a></li><li><a class="nounderline abstract_t">Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210.</a></li><li><a class="nounderline abstract_t">Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343.</a></li><li><a class="nounderline abstract_t">Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399.</a></li><li><a class="nounderline abstract_t">File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.</a></li><li><a class="nounderline abstract_t">Karki A, Thurm C, Cervellione K. Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital. J Community Hosp Intern Med Perspect 2017; 7:300.</a></li><li><a class="nounderline abstract_t">Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract (1995) 2015; 43:144.</a></li><li><a class="nounderline abstract_t">Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.</a></li><li><a class="nounderline abstract_t">Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621.</a></li><li><a class="nounderline abstract_t">Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582.</a></li><li><a class="nounderline abstract_t">Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.</a></li><li><a class="nounderline abstract_t">Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008; 14:116.</a></li><li><a class="nounderline abstract_t">Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138.</a></li><li><a class="nounderline abstract_t">Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356.</a></li><li><a class="nounderline abstract_t">Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.</a></li><li><a class="nounderline abstract_t">Cervera C, Castañeda X, de la Maria CG, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 2014; 58:1668.</a></li><li><a class="nounderline abstract_t">Sandrock CE, Shorr AF. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis 2015; 61 Suppl 2:S79.</a></li><li class="breakAll">FDA news release. FDA approves Vibativ for hospitalized patients with bacterial pneumonia. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm (Accessed on October 09, 2013).</li><li class="breakAll">VIBATIV (telavancin) - Highlights of prescribing information. http://www.vibativ.com/docs/VIBATIV_PI_Final.pdf (Accessed on October 09, 2013).</li><li><a class="nounderline abstract_t">Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011; 52:31.</a></li><li><a class="nounderline abstract_t">Corey GR, Kollef MH, Shorr AF, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030.</a></li><li class="breakAll">Noel GJ, Strauss RS, Shah A, et al. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. Poster K-486. Interscience Conference on Antimicrobial Agents and Chemotherapy and Infectious Diseases Society of America, Washington, DC 2008.</li><li class="breakAll">US Food and Drug Administration (FDA). FDA drug safety communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed on September 02, 2010).</li><li class="breakAll">US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on October 09, 2013).</li><li><a class="nounderline abstract_t">Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140.</a></li><li><a class="nounderline abstract_t">Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.</a></li><li><a class="nounderline abstract_t">Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34:1364.</a></li><li><a class="nounderline abstract_t">Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34:1434.</a></li><li><a class="nounderline abstract_t">Dallas J, Brown SM, Hock K, et al. Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care 2011; 56:412.</a></li><li><a class="nounderline abstract_t">Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008; 31:356.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Trouillet JL, Chastre J. Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2011; 32:181.</a></li><li><a class="nounderline abstract_t">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498.</a></li><li><a class="nounderline abstract_t">de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16:819.</a></li><li><a class="nounderline abstract_t">Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; :CD007577.</a></li><li><a class="nounderline abstract_t">Daghmouri MA, Dudoignon E, Chaouch MA, et al. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine 2023; 58:101880.</a></li><li><a class="nounderline abstract_t">Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.</a></li><li><a class="nounderline abstract_t">Klompas M. Set a short course but follow the patient's course for ventilator-associated pneumonia. Chest 2013; 144:1745.</a></li><li><a class="nounderline abstract_t">Bouglé A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med 2022; 48:841.</a></li><li><a class="nounderline abstract_t">Klompas M, Li L, Menchaca JT, et al. Ultra-Short-Course Antibiotics for Patients With Suspected Ventilator-Associated Pneumonia but Minimal and Stable Ventilator Settings. Clin Infect Dis 2017; 64:870.</a></li><li><a class="nounderline abstract_t">Deshpande A, Klompas M, Guo N, et al. Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis 2023; 77:174.</a></li><li><a class="nounderline abstract_t">Vardakas KZ, Voulgaris GL, Maliaros A, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 2018; 18:108.</a></li><li><a class="nounderline abstract_t">Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.</a></li><li><a class="nounderline abstract_t">Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102:407.</a></li><li><a class="nounderline abstract_t">Luyt CE, Combes A, Nieszkowska A, et al. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009; 22:154.</a></li><li><a class="nounderline abstract_t">Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009; 29:1054.</a></li><li><a class="nounderline abstract_t">Rattanaumpawan P, Lorsutthitham J, Ungprasert P, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010; 65:2645.</a></li><li><a class="nounderline abstract_t">Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol 2013; 13:45.</a></li><li><a class="nounderline abstract_t">Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest 2013; 144:1768.</a></li><li><a class="nounderline abstract_t">Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2005; 3:445.</a></li><li><a class="nounderline abstract_t">Solé-Lleonart C, Rouby JJ, Blot S, et al. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis. Anesthesiology 2017; 126:890.</a></li><li><a class="nounderline abstract_t">Rello J, Rouby JJ, Sole-Lleonart C, et al. Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect 2017; 23:640.</a></li><li><a class="nounderline abstract_t">Zampieri FG, Nassar AP Jr, Gusmao-Flores D, et al. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care 2015; 19:150.</a></li><li><a class="nounderline abstract_t">Qin JP, Huang HB, Zhou H, et al. Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 2021; 11:6969.</a></li><li><a class="nounderline abstract_t">Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015; 43:527.</a></li><li><a class="nounderline abstract_t">Zhang X, Cui X, Jiang M, et al. Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: A systematic review and meta-analysis. J Crit Care 2023; 77:154315.</a></li><li><a class="nounderline abstract_t">Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13:665.</a></li><li><a class="nounderline abstract_t">Steen J, Vansteelandt S, De Bus L, et al. Attributable Mortality of Ventilator-associated Pneumonia. Replicating Findings, Revisiting Methods. Ann Am Thorac Soc 2021; 18:830.</a></li><li><a class="nounderline abstract_t">Jones BE, Sarvet AL, Ying J, et al. Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria. JAMA Netw Open 2023; 6:e2314185.</a></li><li><a class="nounderline abstract_t">Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27:158.</a></li><li><a class="nounderline abstract_t">Rello J, Rué M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862.</a></li><li><a class="nounderline abstract_t">Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 Suppl 4:S131.</a></li><li><a class="nounderline abstract_t">Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93:318.</a></li><li><a class="nounderline abstract_t">Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262.</a></li><li><a class="nounderline abstract_t">Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281.</a></li><li><a class="nounderline abstract_t">Leroy O, Meybeck A, d'Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003; 29:2170.</a></li><li><a class="nounderline abstract_t">Mirsaeidi M, Peyrani P, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score. Clin Infect Dis 2009; 49:72.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf (Accessed on December 02, 2013).</li><li><a class="nounderline abstract_t">Palmore TN, Henderson DK. Managing transmission of carbapenem-resistant enterobacteriaceae in healthcare settings: a view from the trenches. Clin Infect Dis 2013; 57:1593.</a></li></ol></div><div id="topicVersionRevision">Topic 6993 Version 79.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28890434" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911939" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Health care-associated pneumonia: perception versus reality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109953" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The challenge of identifying resistant-organism pneumonia in the emergency department: still navigating on the erie canal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22248977" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is healthcare-associated pneumonia a distinct entity needing specific therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690616" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398862" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889729" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Should nursing home-acquired pneumonia be treated as nosocomial pneumonia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270053" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109951" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26856838" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16963676" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10766680" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951600" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36196032" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic Initiation Timing and Mortality in Trauma Patients With Ventilator-Associated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18359426" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137378" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733044" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27029307" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32297949" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996961" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial-associated harm in critical care: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35617987" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30845116" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vital Signs: Trends in Staphylococcus aureus Infections in Veterans Affairs Medical Centers - United States, 2005-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242356" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207816" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999080" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35394515" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22899745" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical and economic outcomes of a prospective antimicrobial stewardship program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091186" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25473028" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215130" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27208772" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26814675" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data--The Influence of Different Parameters in a Routine Clinical Microbiology Laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24887215" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Weighted-incidence syndromic combination antibiograms to guide empiric treatment of critical care infections: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438467" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prophylactic Antimicrobial Therapy for Acute Aspiration Pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36172891" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The importance of viruses in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36172891" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The importance of viruses in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30208454" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254862" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020404" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484510" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484510" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563344" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28739780" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993338" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545346" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785589" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400759" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400759" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30270406" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32094128" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37182534" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329088" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322268" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31779711" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23568605" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355172" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127058" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29088001" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222460" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acute kidney injury following the concurrent administration of antipseudomonalβ-lactams and vancomycin: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37837651" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33720350" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723282" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32519003" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254432" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28137813" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33517926" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association between a rapid diagnostic test to detect methicillin-resistant Staphylococcus Aureus pneumonia and decreased vancomycin use in a medical intensive care unit over a 30-month period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776365" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL: A Pilot Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065604" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21256087" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nosocomial pneumonia: de-escalation is what matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21867820" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685011" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430237" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25091790" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067350" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29147471" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956849" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569969" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106348" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247123" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452488" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516395" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076672" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060545" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558550" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742831" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647021" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316561" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316561" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316561" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148517" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419353" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419353" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419353" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419353" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846586" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467668" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Excess deaths associated with tigecycline after approval based on noninferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797133" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097417" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421435" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255510" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959634" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21506054" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025194" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947523" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26301604" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36911269" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625336" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297114" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Set a short course but follow the patient's course for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35552788" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034888" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ultra-Short-Course Antibiotics for Patients With Suspected Ventilator-Associated Pneumonia but Minimal and Stable Ventilator Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37011018" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102324" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prolonged versus short-term intravenous infusion of antipseudomonalβ-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080101" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18060758" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19276883" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Aerosolized antibiotics to treat ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19698010" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876621" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24274315" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989805" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954860" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28248714" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28347790" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887226" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33772055" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25493971" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37120926" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23622939" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33285078" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Attributable Mortality of Ventilator-associated Pneumonia. Replicating Findings, Revisiting Methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37200031" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387949" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Appropriateness and delay to initiate therapy in ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366771" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017862" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3338299" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Nosocomial pneumonia. A multivariate analysis of risk and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114368" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682456" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680112" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480582" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480582" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Predicting mortality in patients with ventilator-associated pneumonia: The APACHE II score versus the new IBMP-10 score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934166" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Managing transmission of carbapenem-resistant enterobacteriaceae in healthcare settings: a view from the trenches.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
